VIDEO: Good phase 2 results reported for gene therapy in wet AMD at 26 weeks
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Laurent Fischer, MD, of Adverum Biotechnologies discusses 26-week results from the phase 2 LUNA study investigating Ixo-vec for neovascular age-related macular degeneration.
When delivered at a dose of 6 × 1010 vg/eye, Ixo-vec (ixoberogene soroparvovec) intravitreal gene therapy showed efficacy in maintaining best corrected visual acuity and central subfield thickness in patients with neovascular AMD, including those with high macular fluid levels at baseline, he said.
Fischer also discussed results from a prespecified survey that gauged the patient experience with Ixo-vec.
Collapse
Wykoff C. Ixoberogene soroparvovec (Ixo-vec) IVT gene therapy for neovascular AMD: First-time 26-week interim analysis results from the phase 2 LUNA study. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts